VENITI Revenue and Competitors

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • VENITI's estimated annual revenue is currently $2.3M per year.(i)
  • VENITI's estimated revenue per employee is $251,000

Employee Data

  • VENITI has 9 Employees.(i)
  • VENITI grew their employee count by 0% last year.

VENITI's People

NameTitleEmail/Phone
1
Senior AssemblerReveal Email/Phone
2
Sr. R&D EngineerReveal Email/Phone
3
R&D EngineerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5M40-18%$10MN/A
#2
$24.8M9929%N/AN/A
#3
$84.1M0N/A$1.2MN/A
#4
$35.6M14230%N/AN/A
#5
$57.5M2296%N/AN/A
#6
$52.7M16825%$129.6MN/A
#7
$21.1M84-3%N/AN/A
#8
$61.2M244-13%N/AN/A
#9
$60.6M19320%$115.5MN/A
#10
$56.2M179-3%$122.9MN/A
Add Company

What Is VENITI?

VENITI is the first medical device company developing a suite of innovative technology and solutions that will provide comprehensive treatment across the venous disease continuum. Venous disease refers to all conditions related to or caused by veins that become diseased or abnormal. This encompasses a broad set of maladies. The venous disease cycle begins when vein walls become weak or damaged, or the valves are stretched or injured, and can no longer prevent reflux (backward flow of blood). Once the veins lose their ability to convey blood without reflux, the progressive venous disease cycle has begun. This is commonly referred to as chronic venous insufficiency, or CVI. The blood will begin to back up into the peripheral veins, causing venous hypertension, potential thrombosis (clotting), and leading to even more damage of the vein walls and valves. This in turn leads to more reflux. The VENITI team of experts in science, technology and business are currently developing the VENITI VICI VENOUS STENT® System. Through this, and other, innovative technology, VENITI will achieve results that sets it apart in addressing the challenges specific to the venous system and venous disease. The VICI VENOUS STENT® is CE marked under the European Medical Devices Directive (93/42/EEC), approved by the Australian Therapeutic Goods Administration and commercially available in Europe and Australia. CAUTION: Investigational device. Limited by United States law to investigational use. VENITI and VICI VENOUS STENT are registered trademarks of VENITI, Inc. ©2016VENITI, Inc. All Rights Reserved. Produced in the U.S.

keywords:N/A

N/A

Total Funding

9

Number of Employees

$2.3M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

VENITI News

2022-04-17 - Global Inferior Vena Cava (IVC) Filter Market 2022 SWOT ...

Boston Scientific Corporation; Cardinal Health; Cook Medical; C. R. Bard; ALN, B. Braun Melsungen; Braile Biomdica; VENITI; Argon Medical...

2022-04-17 - Global Venous Stents Market 2022 Industry Growth – Boston ...

Medtronic; Veniti; Cook Medical; Optimed Med; C. R. Bard. The following market segments can be applied to the product: 10 mm Stent...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.7M9N/AN/A
#2
$0.7M9N/AN/A
#3
$0.7M9N/AN/A
#4
$0.7M9N/AN/A
#5
$0.7M9N/AN/A